Literature DB >> 12113105

Therapeutic management of primary CNS lymphoma in immunocompetent patients.

M Reni1, A J Ferreri.   

Abstract

The best therapeutic management in primary CNS lymphomas remains to be defined because of the small size and short follow-up of retrospective series, the methodological pitfalls and limited number of prospective studies, and the paucity of randomized trials. The purpose of this article is to analyze, discuss and summarize the current therapeutic approaches, namely chemotherapy or radiotherapy as exclusive treatment, combined treatment, most commonly used drugs, intrathecal chemotherapy and consolidation radiotherapy and to provide recommendations for ordinary clinical practice. Some important therapeutic issues such as the management of intraocular lymphomas, elderly patients and patients without histological diagnosis, as well as the relevance of salvage therapy as a playground for the evaluation of new drugs are also analyzed. Finally, the main open questions as well as current and expected investigation trends are discussed.

Entities:  

Mesh:

Year:  2001        PMID: 12113105     DOI: 10.1586/14737140.1.3.382

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  2 in total

1.  CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.

Authors:  Nadia N Laack; Brian Patrick O'Neill; Karla V Ballman; Judith Rich O'Fallon; Xiomara W Carrero; Paul J Kurtin; Bernd W Scheithauer; Paul D Brown; Thomas M Habermann; Joseph P Colgan; Mark R Gilbert; Roland B Hawkins; Roscoe F Morton; Harry E Windschitl; Tom R Fitch; Eduardo R Pajon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-26       Impact factor: 7.038

2.  The diagnostic properties of frozen sections in suspected intracranial tumors: A study of 578 consecutive cases.

Authors:  Kathrine Tofte; Cathrine Berger; Sverre Helge Torp; Ole Solheim
Journal:  Surg Neurol Int       Date:  2014-12-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.